Communications Biology (Feb 2023)
MacroH2A histone variants modulate enhancer activity to repress oncogenic programs and cellular reprogramming
- Wazim Mohammed Ismail,
- Amelia Mazzone,
- Flavia G. Ghiraldini,
- Jagneet Kaur,
- Manvir Bains,
- Amik Munankarmy,
- Monique S. Bagwell,
- Stephanie L. Safgren,
- John Moore-Weiss,
- Marina Buciuc,
- Lynzie Shimp,
- Kelsey A. Leach,
- Luis F. Duarte,
- Chandandeep S. Nagi,
- Saul Carcamo,
- Chi-Yeh Chung,
- Dan Hasson,
- Neda Dadgar,
- Jian Zhong,
- Jeong-Heon Lee,
- Fergus J. Couch,
- Alexander Revzin,
- Tamas Ordog,
- Emily Bernstein,
- Alexandre Gaspar-Maia
Affiliations
- Wazim Mohammed Ismail
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- Amelia Mazzone
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- Flavia G. Ghiraldini
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai
- Jagneet Kaur
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- Manvir Bains
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- Amik Munankarmy
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- Monique S. Bagwell
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- Stephanie L. Safgren
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- John Moore-Weiss
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- Marina Buciuc
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- Lynzie Shimp
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- Kelsey A. Leach
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- Luis F. Duarte
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai
- Chandandeep S. Nagi
- Department of Pathology and Immunology, Baylor College of Medicine
- Saul Carcamo
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai
- Chi-Yeh Chung
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai
- Dan Hasson
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai
- Neda Dadgar
- Department of Physiology and Biomedical Engineering, Mayo Clinic
- Jian Zhong
- Center for Individualized Medicine, Epigenomics program, Mayo Clinic
- Jeong-Heon Lee
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- Fergus J. Couch
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- Alexander Revzin
- Department of Physiology and Biomedical Engineering, Mayo Clinic
- Tamas Ordog
- Center for Individualized Medicine, Epigenomics program, Mayo Clinic
- Emily Bernstein
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai
- Alexandre Gaspar-Maia
- Division of Experimental Pathology, Department of Lab Medicine and Pathology, Mayo Clinic
- DOI
- https://doi.org/10.1038/s42003-023-04571-1
- Journal volume & issue
-
Vol. 6,
no. 1
pp. 1 – 19
Abstract
MacroH2A histone variants are shown to mark a subset of enhancers in both normal and cancer cells. In mice, macroH2A deficiency is shown to facilitate increased activity of transcription stem cell-associated transcription factors.
